Health Care

Gilead Sciences’ stock gains reflect investor confidence in its drug pipeline, driving a broader healthcare sector rebound in late October 2026.

Thomas J. Appio steps in as interim CEO of Bausch + Lomb, raising 2026 guidance amid a strategic review—see the latest outlook and impact.

Integra LifeSciences secures $450 M in 9.50% senior secured notes to refinance debt, boost yields, and fund innovation in orthopedic and neurosurgical markets.

Discover how Clover Health’s 5‑star Medicare Advantage rating boosts 2028 payments, attracts members, and fuels investor confidence in 2026.

Mirum Pharma reports maralixibat hits primary endpoint in cholestatic liver disease trial, paving way for Phase III EXPAND data and investor insights.

Discover how AstraZeneca’s new US R&D hub, stellar investor returns, and phase‑III results for efzimfotase alfa shape its 2026 strategy and market outlook.

Discover why KARDIGAN INC’s stock swings from $27 to $12, its $1.37B market cap, and a negative P/E ratio—what it means for investors in health‑care.

Virax Biolabs pivots to a leaner team, boosting its ViraxImmune immunology R&D while trimming costs – a strategic shift for future growth.

Discover how Formycon AG’s biosimilar expertise positions it to thrive as drug patents expire, driving biotech growth and cost‑effective pharma solutions.

Biofrontera AG: German biopharma leader driving dermatological drug & medical cosmetic innovation, strong valuation & global reach.